Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.07
0.020.20%
At close: Feb 13, 4:00 PM EST
$10.07
N/A
After Hours: Feb 13, 4:00 PM EST
Comments
Loading...
Design Therapeutics Inc (DSGN) Stock Price, Quote, News & History
DSGNNASDAQ
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Design Therapeutics (DSGN) stock?
You can purchase shares of Design Therapeutics (NASDAQ:DSGN) through any online brokerage.
Who are Design Therapeutics (DSGN) competitors?
Other companies in Design Therapeutics’s space includes: 4D Molecular Therapeutics Inc (NASDAQ:FDMT), Upstream Bio Inc (NASDAQ:UPB), Replimune Group Inc (NASDAQ:REPL), Altimmune Inc (NASDAQ:ALT) and ADC Therapeutics SA (NYSE:ADCT).
What is the forecast, or price target, for Design Therapeutics (DSGN) stock?
Design Therapeutics has a consensus price target of $11.33.
What is the current price for Design Therapeutics (DSGN)?
The stock price for Design Therapeutics (NASDAQ: DSGN) is $10.07 last updated February 13, 2026 at 4:00 PM EST.
Does Design Therapeutics (DSGN) pay a dividend?
There are no upcoming dividends for Design Therapeutics.
When is Design Therapeutics (NASDAQ:DSGN) reporting earnings?
Design Therapeutics does not have any upcoming earnings scheduled.
Is Design Therapeutics (DSGN) going to split?
There is no upcoming split for Design Therapeutics.
What sector and industry does Design Therapeutics (DSGN) operate in?
Design Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
